Inga Deakin

Puridify Ltd. develops bioprocessing technologies. It develops a platform purification technology that will improve processing opportunities and reduce costs. The company was founded by Oliver Hardick, Iwan Thomas Roberts and Thomas Edward Haywood in 2013 and is headquartered in Stevenage, the United Kingdom.

Ieso Digital Health Ltd. provides Internet enabled mental health services to health providers, private individuals and businesses. The firm engages in delivering cognitive behavioral therapy. It offers anxiety, bereavement, child and family, depression, drug and alcohol misuse, eating disorder, managing anger, managing pain, obsessive compulsive disorder, panic, phobia, post traumatic stress, relationship, sexual difficulty, sports psychology, stress management, and terminal illness therapy services. The company was founded by Barnaby Perks, Sue Wright and Nadine Field in 2000 and is headquartered in Cambridge, the United Kingdom.

Touchstone Innovations Investment Management Ltd. is a Venture Capital firm, a subsidiary of Touchstone Innovations Ltd. founded in 1986. Touchstone Innovations Investment Management Ltd. is headquartered in London.

Molten Ventures (Private Equity) (Molten Ventures) is a venture capital firm subsidiary of Molten Ventures Plc founded in 1998 by Simon Christopher Cook and Stuart Malcolm Chapman. The firm is headquartered in London, United Kingdom.

Inivata Ltd. develops new clinical applications for ctDNA analysis. It is a clinical cancer genomics company harnessing the potential of circulating tumour DNA (ctDNA) analysis to improve cancer testing and treatment. The firm is focused on developing clinical applications of ctDNA through collaborations with clinical oncologists at prominent academic institutions, leading community treatment centres and innovative biopharmaceutical companies. The company was founded by James Brenton, Tim Forshew, Rosenfeld Nitzan and Davina Gale on July 23, 2014 and is headquartered in Cambridge, the United Kingdom.

ApcinteX Ltd. develops and markets anticoagulant APC pathway to treat haemophilia. The company is headquartered in London, the United Kingdom.

Oxular Ltd. engages in research and experimental development on biotechnology. The firm develops retinal treatments to access specific small spaces in the eye and to provide drug distribution to tissues involved in retinal diseases. The company was founded by Tom Cavanagh and Ronald K. Yamamoto in 2014 and is headquartered in Oxford, the United Kingdom.

Veryan Medical Ltd. develops and commercializes novel vascular stent technology. The firm's products are designed to clinical performance and bio-mechanical performance of stented vessels. The company was founded by Colin G. Caro, Charles Richard Taylor and Paul Burke Gilson in 2003 and is headquartered in Oxford, the United Kingdom.